Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.05 (2.78%)
Bid:
1.70
Ask:
2.00
Spread: 0.30 (17.647%)
Market Cap: £8.08m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Total Voting Rights

31 Jul 2020 16:31

RNS Number : 8003U
Renalytix AI PLC
31 July 2020
 

 

 

Renalytix AI plc

(the "Company") 

 

Total Voting Rights

 

For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following:

 

As of 31 July 2020, the Company's issued and fully paid share capital consists of 72,029,634 ordinary shares with a nominal value of £0.0025 each ("Ordinary Shares"), with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. The total number of voting rights in the Company is therefore 72,029,634.

 

The above figure of 72,029,634 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR

Stifel (Nominated Adviser)

Tel: 020 7710 7600

Alex Price / Nicholas Moore

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVRFFLFXBDLEBBL
Date   Source Headline
1st Apr 20197:00 amRNSPublication of confirmation study results
25th Mar 20197:00 amRNSHalf-year Report
22nd Mar 20197:00 amRNSRenalytixAI Forms Core Investigator Group
12th Mar 20197:00 amRNSInvestor briefing
14th Feb 20197:00 amRNSAppointment of Nomad and Joint Broker
13th Feb 20197:00 amRNSJoint venture partnership agreement with AKESOgen
6th Feb 20197:00 amRNSRenalytixAI Expands Leadership Team
23rd Jan 20197:00 amRNSInitiates Clinical Validation Study
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
2nd Jan 20197:00 amRNSExercise of Option for Exclusive License
20th Dec 20185:20 pmRNSDirector/PDMR Shareholding
20th Dec 20187:01 amRNSPlanned appointment of joint broker & of NOMAD
19th Dec 20186:28 pmRNSDirector Dealing
17th Dec 20181:30 pmRNSHolding(s) in Company
9th Nov 201810:30 amRNSHolding(s) in Company
8th Nov 20184:50 pmRNSHolding(s) in Company
8th Nov 20187:00 amRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.